Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare’s ACO Final Rule Responds To Provider Concerns, But Leaves Device Industry Dissatisfied

This article was originally published in The Gray Sheet

Executive Summary

Although CMS’ newly finalized rule on accountable care organizations has allayed health care providers’ fears of a program too burdensome to bother with, medical device manufacturers remain worried that ACOs will curb patient access to their products.

You may also be interested in...



Marilyn Tavenner Stepping Down From CMS

CMS principal deputy administrator Andy Slavitt steps in as acting administrator as Marilyn Tavenner plans to depart the agency after five years running the agency. She will leave at the end of February.

Industry Says OIG Proposed Gainsharing Rule Could Hurt Innovation

Medical device groups worry some that proposed provisions and interpretations in a draft OIG rule could expand exemptions for gainsharing agreements between hospitals and physicians that will hinder the ability of innovative products to gain traction in the market.

Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily

Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel